acute myeloid leukemia refractory
Showing 1 - 17 of 17
Acute Myeloid Leukemia Refractory Trial in Lyon (NP137, Azacitidine Injection, Venetoclax)
Recruiting
- Acute Myeloid Leukemia Refractory
- NP137
- +2 more
-
Lyon, FranceCentre Léon Bérard
Nov 30, 2023
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (CB-012)
Not yet recruiting
- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory
- (no location specified)
Nov 9, 2023
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)
Recruiting
- Acute Myeloid Leukemia Refractory
- Acute Myeloid Leukemia, in Relapse
- anti Tim-3/CD123 CAR-T cell therapy
-
Xuzhou, Jiangsu, ChinaKailin Xu
Nov 4, 2023
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Myeloid Leukemia Trial in United States
Recruiting
- Refractory Acute Myeloid Leukemia
- +4 more
- CD371-YSNVZ-IL18 CAR T cells
-
Basking Ridge, New Jersey
- +6 more
Aug 29, 2023
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial in Germany (Cyclophosphamide (Non-IMP,
Not yet recruiting
- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory
- Cyclophosphamide (Non-IMP, Lymphodepletion)
- +3 more
-
Ulm, Baden-Württemberg, Germany
- +4 more
Jul 24, 2023
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, Granulocytic Sarcoma Trial in Winston-Salem (drug,
Not yet recruiting
- Acute Myeloid Leukemia, in Relapse
- +2 more
- CPI 613
- +3 more
-
Winston-Salem, North CarolinaWake Forest Baptist Comprehensive Cancer Center
May 10, 2023
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial in Boston (Iadademstat, Gilteritinib Oral Tablet)
Recruiting
- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory
- Iadademstat
- Gilteritinib Oral Tablet
-
Boston, Massachusetts
- +2 more
Jan 18, 2023
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia Recurrent Trial in Beijing (CD123-CAR-NK cells)
Recruiting
- Acute Myeloid Leukemia Refractory
- Acute Myeloid Leukemia Recurrent
- CD123-CAR-NK cells
-
Beijing, Beijing, ChinaThe Fifth Medical Center of Chinese People's Liberation Army (PL
Oct 24, 2022
Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Seattle (SC-DARIC33)
Recruiting
- Acute Myeloid Leukemia
- +2 more
- SC-DARIC33
-
Seattle, WashingtonSeattle Children's Hospital
Sep 6, 2022
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial in Edegem, Roeselare (Venetoclax, 6-mercaptopurine)
Recruiting
- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory
-
Edegem, Antwerp, Belgium
- +1 more
Aug 16, 2022
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti-siglec-6 CAR-T cell therapy)
Recruiting
- Acute Myeloid Leukemia Refractory
- Acute Myeloid Leukemia, in Relapse
- anti-siglec-6 CAR-T cell therapy
-
Xuzhou, Jiangsu, ChinaKailin Xu
Aug 2, 2022
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, Myelodysplastic Syndrome Trial in Zhengzhou (6MW3211
Not yet recruiting
- Acute Myeloid Leukemia, in Relapse
- +2 more
- 6MW3211 injection with Intravenous Infusion
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital
Jul 2, 2022
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndrome Acute Myeloid Leukemia Trial in
Recruiting
- Acute Myeloid Leukemia Refractory
- +2 more
-
Houston, Texas
- +4 more
Jun 23, 2022
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (Venetoclax, Azacitadine, Vorinostat)
Not yet recruiting
- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory
- Venetoclax
- +5 more
- (no location specified)
Apr 11, 2022
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (BP1002; Liposomal Bcl-2 Antisense
Not yet recruiting
- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory
- BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide
- Decitabine (in combination with BP1002)
- (no location specified)
Mar 8, 2022
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, Relapsed, Adult Trial in Nijmegen (UCB-NK cells, IL-2)
Recruiting
- Acute Myeloid Leukemia Refractory
- Acute Myeloid Leukemia, Relapsed, Adult
- UCB-NK cells
- IL-2
-
Nijmegen, NetherlandsRadboud University Medical Center
Nov 10, 2021